" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "

Not Applicable

Not yet recruiting

• Conditions: Immune Thrombocytopenic Purpura
• Interventions: Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism

• Registration Number: NCT05585944
• Lead Sponsor: Sohag University

Brief Summary

Immune thrombocytopenia is an acquired autoimmune disease, in which platelets are opsonized by auto-antibodies and destroyed by phagocytic cells .Genetic polymorphisms in the immune mediators have been suggested to play a pivotal role in the pathogenesis of many autoimmune disorders . Several genetic polymorphisms of the immune system genes have been described in ITP such as interleukins, tumor necrosis factors (TNF) alpha and beta, and interferon-gamma., These polymorphisms were found to be associated with an increased risk of ITP progression or exacerbation .CD40 is a co-stimulatory 4348 kDa glycoprotein molecule composed of 277 amino acid residues which belongs to the tumor necrosis family. It is encoded by a gene which is located at chromosome 20q11-13, expressed mainly on antigen presenting cells (APCs), some non-immune cells and tumors.Antinuclear antibodies (ANA) is a collective term for a large and heterogeneous group of circulating autoantibody. Reflecting their clinical importance, ANA are diagnostic, prognostic or classification criteria for many autoimmune diseases.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-10
• Study First Submitted: 2022-10-16
• Study First Submitted QC: 2022-10-16
• Last Update Submitted: 2022-10-16
• Study First Posted: 2022-10-19
• Last Update Posted: 2022-10-19
• Study Start: 2022-11-01
• Primary Completion: 2023-05-01
• Study Completion: 2023-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• sign an informed written consent from the patients or their parents
• patient with newly diagnosed ITP
• patient age > 1 year and < 65 years and both sexes are included.

Read More

Exclusion Criteria

• Refusal to sign an informed written consent
• patient with persistent ITP, patient with secondary immune thrombocytopenia
• patient age < 1 year or > 65 years.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control	Genotyping of rs1883832C/T related single-nucleotide polymorphism	healthy participants
cases	Genotyping of rs1883832C/T related single-nucleotide polymorphism	cases of immune thrombocytopenic purpura

Primary Outcome Measures

Name	Time	Method
rs1883832C/T related single-nucleotide polymorphism	6 months	effect of single-nucleotide polymorphism of CD40 gene (rs1883832 C/T) on the risk of immune thrombocytopenic purpura

Secondary Outcome Measures

Name	Time	Method
ANA	6 months	ANA in immune thrombocytopenic purpura

Trial Locations

Locations (1)

Sohag University hospitals; 🇪🇬 Sohag, Egypt